Genmab Plots $500m Nasdaq IPO
Some 20 years after its birth, the Danish biotech has decided the time is right to go west and raise cash through a US listing to drive its pipeline forward.
Some 20 years after its birth, the Danish biotech has decided the time is right to go west and raise cash through a US listing to drive its pipeline forward.